The messy complexities of democratic engagement and empowerment in participatory design – an illustrative case with a community-based organisation.

Autor: Thinyane, Mamello¹ (AUTHOR) mamello@unu.edu, Bhat, Karthik² (AUTHOR), Goldkind, Lauri³ (AUTHOR), Cannanure, Vikram Kamath⁴ (AUTHOR)

Publikováno v: CoDesign. Mar2020, Vol. 16 Issue 1, p29-44. 16p. 3 Color Photographs, 1 Diagram, 1 Chart.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.

Autor: Partridge AH; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Niman SM; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Ruggeri M; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Peccatori FA; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Azim HA Jr; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Colleoni M; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Saura C; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Shimizu C; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Sætersdal AB; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Kroep JR; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Mailliez A; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Warner E; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Borges VF; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Amant F; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Gombos A; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Kataoka A; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Rousset-Jablonski C; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Borstnar S; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Takei J; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Lee JE; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Walshe JM; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Ruíz-Borrego M; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Moore HCF; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Saunders C; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Bjelic-Radisic V; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Susnjar S; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Cardoso F; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Smith KL; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Ferreiro T; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Ribi K; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Ruddy K; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Kammler R; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., El-Abed S; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Viale G; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Piccart M; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Korde LA; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Goldhirsch A; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Gelber RD; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy)., Pagani O; From the Department of Medical Oncology, Dana-Farber Cancer Institute (A.H.P.), Harvard Medical School (A.H.P., R.D.G.), the International Breast Cancer Study Group Statistical Center and the Department of Data Science, Division of Biostatistics, Dana-Farber Cancer Institute (S.M.N., R.D.G.), and Frontier Science and Technology Research Foundation and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the International Breast Cancer Study Group (M.R., K. Ribi, R.K., G.V., A. Goldhirsch) and the Swiss Group for Clinical Cancer Research (O.P.), Bern, the Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Geneva (O.P.), and University Hospitals, Lugano University, Lugano (O.P.) - all in Switzerland; the European Institute of Oncology, Scientific Institutes for Research, Hospitalization and Healthcare (IRCCS) (F.A.P., M.C., G.V., A. Goldhirsch), Milan; the Breast Cancer Center, Hospital Zambrano Hellion, School of Medicine, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico (H.A.A.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, and SOLTI Breast Cancer Research Group (C. Saura) and Soul Reconnect (T.F.), Barcelona, GEICAM Spanish Breast Cancer Research Group, Madrid (M.R.-B.), and Hospital Virgen del Rocio de Sevilla, Seville (M.R.-B.) - all in Spain; the Department of Breast and Medical Oncology, National Center for Global Health and Medicine (C. Shimizu), Breast Oncology Center, the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (A.K.), and St. Luke's International Hospital, Breast Center (J.T.) - all in Tokyo; the Breast Cancer Unit, Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo (A.B.S.); the Department of Medical Oncology, Leiden University Medical Center, Leiden (J.R.K.), and Antoni van Leeuwenhoek-Netherlands Cancer Institute, Amsterdam (F.A.) - both in the Netherlands; the Department of Medical Oncology, Centre Oscar Lambret, Lille (A.M.), and the Department of Surgery, Leon Berard Cancer Center, Centre Léon Bérard, Lyon (C.R.-J.) - both in France; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto (E.W.); the Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, Aurora (V.F.B.); the Department of Oncology, KU Leuven and Leuven Cancer Institute, and the Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven (F.A.), and Institut Jules Bordet and Université Libre de Bruxelles (A. Gombos, M.P.) and Breast International Group (S.E.-A.), Brussels - all in Belgium; the Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia (S.B.); the Breast Division, Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, and the Department of Clinical Research and Evaluation, Samsung Advanced Institute for Health Sciences and Technology, Sungkyunkwan University - both in Seoul, South Korea (J.E.L.); Cancer Trials Ireland, the Department of Medical Oncology, St. Vincent's University Hospital, and Tallaght University Hospital - all in Dublin (J.M.W.); the Breast Oncology Program, Cleveland Clinic Taussig Cancer Institute, Cleveland (H.C.F.M.); the Department of Surgery, Centre for Cancer Research, Melbourne Medical School, and the Royal Melbourne Hospital, University of Melbourne - both in Melbourne, VIC, Australia (C. Saunders); the Breast Unit, Helios University Hospital Wuppertal, University Witten-Herdecke, Wuppertal, Germany (V.B.-R.); the Department of Obstetrics and Gynecology, Medical University of Graz, Graz, Austria (V.B.-R.); the Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade (S.S.); the Breast Unit, Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore (K.L.S.), and Breast Cancer and Melanoma Therapeutics, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda (L.A.K.) - both in Maryland; and the Department of Oncology, Mayo Clinic, Rochester, MN (K. Ruddy).

Publikováno v: The New England journal of medicine [N Engl J Med] 2023 May 04; Vol. 388 (18), pp. 1645-1656.

Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer.

Autor: Tutt ANJ; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Garber JE; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Kaufman B; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Viale G; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Fumagalli D; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Rastogi P; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Gelber RD; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., de Azambuja E; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Fielding A; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Balmaña J; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Domchek SM; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Gelmon KA; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Hollingsworth SJ; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Korde LA; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Linderholm B; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Bandos H; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Senkus E; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Suga JM; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Shao Z; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Pippas AW; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Nowecki Z; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Huzarski T; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Ganz PA; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Lucas PC; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Baker N; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Loibl S; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., McConnell R; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Piccart M; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Schmutzler R; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Steger GG; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Costantino JP; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Arahmani A; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Wolmark N; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., McFadden E; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Karantza V; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Lakhani SR; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Yothers G; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Campbell C; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston., Geyer CE Jr; From the Breast Cancer Now Toby Robins Research Centre, the Institute of Cancer Research (A.N.J.T.), and the Breast Cancer Now Unit, Guy's Hospital Cancer Centre, King's College London (A.N.J.T.), London, AstraZeneca, Cambridge (S.J.H., N.B.), and Frontier Science (Scotland), Kincraig (R.M.C., E.M.F., C.C.) - all in the United Kingdom; Dana-Farber Cancer Institute, Harvard Medical School (J.E.G., R.D.G.), Frontier Science Foundation (R.D.G.), and Harvard T.H. Chan School of Public Health (R.D.G.) - all in Boston; the Breast Oncology Institute, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (B.K.); the University of Milan, European Institute of Oncology IRCCS, Milan (G.V.); Breast International Group (D.F., A.A.) and Institut Jules Bordet, l'Université Libre de Bruxelles (E.A., M.P.), Brussels; NRG Oncology (P.R., H.B., P.C.L., N.W., G.Y., C.E.G.) and the Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania (S.M.D.), Philadelphia, and the UPMC Hillman Cancer Center (P.R., P.C.L., N.W.) and the Department of Biostatistics (H.B., J.P.C., G.Y.), University of Pittsburgh, and the NSABP Foundation (N.W.), Pittsburgh - all in Pennsylvania; AstraZeneca, Gaithersburg (A.F.), and the National Cancer Institute, Rockville (L.A.K.) - both in Maryland; Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital (J.B.) - both in Barcelona; BC Cancer, Vancouver, BC, Canada (K.A.G.); Sahlgrenska University Hospital (B.L.) and the Institute of Clinical Sciences, Department of Oncology, Sahlgrenska Academy, Gothenburg University (B.L.) - both in Gothenburg, Sweden; the Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk (E.S.), the Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw (Z.N.), the International Hereditary Cancer Center, Pomeranian Medical University, Szczecin (T.H.), and Read-Gene, Grzepnica (T.H.) - all in Poland; Kaiser Permanente Vallejo Medical Center, Vallejo (J.M.S.), and the UCLA Fielding School of Public Health, David Geffen School of Medicine at UCLA (P.A.G.), and the UCLA Jonsson Comprehensive Cancer Center (P.A.G.), Los Angeles - all in California; Fudan University Shanghai Cancer Center, Shanghai, China, (Z.S.); Georgia NCORP, Northside Hospital Cancer Institute (A.W.P.), and Piedmont Healthcare (A.W.P.) - both in Atlanta; German Breast Group, Neu-Isenburg (S.L.), the Center for Hematology and Oncology Bethanien and Goethe University, Frankfurt (S.L.), and the Center for Familial Breast and Ovarian Cancer and the Center for Integrated Oncology, Faculty of Medicine, University Hospital Cologne, Cologne (R.S.) - all in Germany; the Department of Internal Medicine I and Gaston H. Glock Research Center, Medical University of Vienna, Vienna (G.G.S.); Merck, Kenilworth, NJ (V.K.); the University of Queensland Centre for Clinical Research and Pathology Queensland (S.R.L.) - both in Brisbane, QLD, Australia; and Houston Methodist Cancer Center (C.E.G.) and Weill Cornell Medical College (C.E.G.) - both in Houston.

Publikováno v: The New England journal of medicine [N Engl J Med] 2021 Jun 24; Vol. 384 (25), pp. 2394-2405. Date of Electronic Publication: 2021 Jun 03.

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.

Autor: Mullane KM; University of Chicago, Department of Medicine, Chicago, IL, USA. Electronic address: kmullane@medicine.bsd.uchicago.edu., Morrison VA; University of Minnesota, Hennepin County Medical Center, Minneapolis, MN, USA., Camacho LH; Oncology Consultants, Houston, TX, USA., Arvin A; Stanford University School of Medicine, Stanford, CA, USA., McNeil SA; Canadian Center for Vaccinology, IWK Health Centre and Nova Scotia Health Authority, Dalhousie University, Halifax, NS, Canada., Durrand J; Merck & Co, Inc, Kenilworth, NJ, USA., Campbell B; Merck & Co, Inc, Kenilworth, NJ, USA., Su SC; Merck & Co, Inc, Kenilworth, NJ, USA., Chan ISF; Merck & Co, Inc, Kenilworth, NJ, USA., Parrino J; Merck & Co, Inc, Kenilworth, NJ, USA., Kaplan SS; Merck & Co, Inc, Kenilworth, NJ, USA., Popmihajlov Z; Merck & Co, Inc, Kenilworth, NJ, USA., Annunziato PW; Merck & Co, Inc, Kenilworth, NJ, USA.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2019 Sep; Vol. 19 (9), pp. 1001-1012. Date of Electronic Publication: 2019 Aug 06.

Placebo-controlled trial to determine the effectiveness of a urea/lactic acid-based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central Cancer Treatment Group Study N05C5.

Autor: Wolf SL; Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA., Qin R, Menon SP, Rowland KM Jr, Thomas S, Delaune R, Christian D, Pajon ER Jr, Satele DV, Berenberg JL, Loprinzi CL

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2010 Dec 10; Vol. 28 (35), pp. 5182-7. Date of Electronic Publication: 2010 Nov 08.